NasdaqCM:AXGN

Stock Analysis Report

Executive Summary

AxoGen, Inc. provides surgical solutions for physical damage or transection to peripheral nerves.

Snowflake

Fundamentals

Excellent balance sheet with limited growth.


Similar Companies

Share Price & News

How has AxoGen's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

6.0%

AXGN

1.9%

US Medical Equipment

0.4%

US Market


1 Year Return

-63.0%

AXGN

15.6%

US Medical Equipment

6.9%

US Market

Return vs Industry: AXGN underperformed the US Medical Equipment industry which returned 15.6% over the past year.

Return vs Market: AXGN underperformed the US Market which returned 6.9% over the past year.


Shareholder returns

AXGNIndustryMarket
7 Day6.0%1.9%0.4%
30 Day-12.4%-1.7%-1.1%
90 Day-34.1%-0.03%-0.5%
1 Year-63.0%-63.0%16.5%15.6%9.3%6.9%
3 Year38.4%38.4%72.1%66.9%45.8%36.4%
5 Year387.8%387.8%125.8%100.8%62.9%45.1%

Price Volatility Vs. Market

How volatile is AxoGen's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is AxoGen undervalued compared to its fair value and its price relative to the market?

3.53x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate AXGN's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate AXGN's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: AXGN is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: AXGN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate AXGN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AXGN is good value based on its PB Ratio (3.5x) compared to the US Medical Equipment industry average (3.8x).


Next Steps

Future Growth

How is AxoGen forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

55.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AXGN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AXGN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AXGN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AXGN's revenue (20.7% per year) is forecast to grow faster than the US market (7.2% per year).

High Growth Revenue: AXGN's revenue (20.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if AXGN's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has AxoGen performed over the past 5 years?

-7.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: AXGN is unprofitable, and losses have increased over the past 5 years at a rate of -7.5% per year.

Accelerating Growth: Unable to compare AXGN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AXGN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).


Return on Equity

High ROE: AXGN has a negative Return on Equity (-18.74%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: AXGN is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: AXGN is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is AxoGen's financial position?


Financial Position Analysis

Short Term Liabilities: AXGN's short term assets ($141.3M) exceeds its short term liabilities ($16.2M)

Long Term Liabilities: AXGN's short term assets (141.3M) exceeds its long term liabilities (2.4M)


Debt to Equity History and Analysis

Debt Level: AXGN is debt free.

Reducing Debt: AXGN currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Inventory Level: AXGN has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if AXGN's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AXGN has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if AXGN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is AxoGen's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate AXGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate AXGN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if AXGN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AXGN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AXGN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of AxoGen's salary, the management and board of directors tenure and is there insider trading?

1.3yrs

Average management tenure


CEO

Karen Zaderej (57yo)

8.1yrs

Tenure

US$3,665,188

Compensation

Ms. Karen Zaderej has been the Chief Executive Officer of AxoGen, Inc. since May 2010 and also has been its President since September 30, 2011. She has been Director of Viveve Medical Inc. since September  ...


CEO Compensation Analysis

Compensation vs. Market: Karen's total compensation ($USD3.67M) is about average for companies of similar size in the US market ($USD1.79M).

Compensation vs Earnings: Karen's compensation has been consistent with company performance over the past year.


Management Age and Tenure

1.3yrs

Average Tenure

54.5yo

Average Age

Experienced Management: AXGN's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Age and Tenure

6.1yrs

Average Tenure

58.5yo

Average Age

Experienced Board: AXGN's board of directors are considered experienced (6.1 years average tenure).


Insider Trading

Insider Buying: AXGN insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$52,38915 Aug 19
Mark Gold
EntityIndividual
Role
Member of the Board of Directors
Director
Shares4,000
Max PriceUS$13.13
BuyUS$85,13914 Aug 19
Isabelle Billet
EntityIndividual
Role
Senior Key Executive
Chief Strategy & Business Development Officer
Shares5,635
Max PriceUS$15.12
BuyUS$30,26014 Aug 19
Maria Martinez
EntityIndividual
Role
Head of Human Resources
Chief Human Resources Officer
Shares2,000
Max PriceUS$15.13
BuyUS$217,67313 Aug 19
Quentin Blackford
EntityIndividual
Role
Member of the Board of Directors
Director
Shares15,535
Max PriceUS$14.10
BuyUS$1,012,42512 Aug 19
Karen Zaderej
EntityIndividual
Role
Chief Executive Officer
Chairman
Shares75,000
Max PriceUS$13.50
BuyUS$101,25014 Jun 19
Amy McBride-Wendell
EntityIndividual
Shares5,000
Max PriceUS$20.25
SellUS$452,60017 May 19
David Hansen
EntityIndividual
Shares20,000
Max PriceUS$22.63
SellUS$645,00015 Nov 18
Gregory Freitag
EntityIndividual
Role
Member of the Board of Directors
General Counsel & Director
Shares20,000
Max PriceUS$32.25
SellUS$829,62015 Nov 18
Karen Zaderej
EntityIndividual
Role
Chief Executive Officer
Chairman
Shares25,000
Max PriceUS$33.42

Ownership Breakdown


Management Team

  • Greg Freitag (57yo)

    General Counsel & Director

    • Tenure: 8.1yrs
    • Compensation: US$856.65k
  • Pete Mariani (55yo)

    Chief Financial Officer

    • Tenure: 3.6yrs
    • Compensation: US$1.44m
  • Karen Zaderej (57yo)

    Chairman

    • Tenure: 8.1yrs
    • Compensation: US$3.67m
  • Eric Sandberg (54yo)

    Chief Commercial Officer

    • Tenure: 0.8yrs
  • Mike Donovan (54yo)

    Vice President of Operations

    • Tenure: 4.1yrs
  • Maria Martinez (51yo)

    Chief Human Resources Officer

    • Tenure: 1yrs
  • Kaila Krum

    Vice President of Investor Relations & Corporate Development

    • Tenure: 1.3yrs
  • Greg Davault (51yo)

    Vice President of Marketing

    • Tenure: 1.3yrs
  • Isabelle Billet (57yo)

    Chief Strategy & Business Development Officer

    • Tenure: 1yrs
  • John Glueck

    Chief Compliance Officer & Assistant General Counsel

    • Tenure: 1yrs

Board Members

  • Guido Neels (71yo)

    Director

    • Tenure: 4.2yrs
    • Compensation: US$169.90k
  • Greg Freitag (57yo)

    General Counsel & Director

    • Tenure: 8.1yrs
    • Compensation: US$856.65k
  • James Grooms (59yo)

    Director

    • Tenure: 8.1yrs
    • Compensation: US$174.90k
  • Robert Rudelius (63yo)

    Director

    • Tenure: 9.1yrs
    • Compensation: US$182.40k
  • Mark Gold (69yo)

    Director

    • Tenure: 8.1yrs
    • Compensation: US$179.90k
  • Bruce Mast

    Member of Board of Advisor

    • Tenure: 0yrs
  • Karen Zaderej (57yo)

    Chairman

    • Tenure: 8.1yrs
    • Compensation: US$3.67m
  • David Muir

    Member of Board of Advisor

    • Tenure: 0yrs
  • Quentin Blackford (40yo)

    Director

    • Tenure: 0.4yrs
  • Amy Wendell (58yo)

    Lead Director

    • Tenure: 1.4yrs
    • Compensation: US$164.90k

Company Information

AxoGen, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: AxoGen, Inc.
  • Ticker: AXGN
  • Exchange: NasdaqCM
  • Founded:
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$486.370m
  • Shares outstanding: 39.26m
  • Website: https://www.axogeninc.com

Number of Employees


Location

  • AxoGen, Inc.
  • 13631 Progress Boulevard
  • Suite 400
  • Alachua
  • Florida
  • 32615
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AXGNNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDOct 2011
LT3DB (Deutsche Boerse AG)YesCommon StockDEEUROct 2011
0HKDLSE (London Stock Exchange)YesCommon StockGBUSDOct 2011

Biography

AxoGen, Inc. provides surgical solutions for physical damage or transection to peripheral nerves. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerv ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/20 00:36
End of Day Share Price2019/10/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.